Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This educational activity is supported by educational grants from Eisai, Inc; Exelixis, Inc; and Merck & Co, Inc.
Community Practice Connection™ :Integrating the Evidence to Optimize Treatment for Patients with Advanced RCC: An Expert Tumor Board Discussion
Release Date: August 31, 2020
Expiration Date: August 31, 2021
This Community Practice Connections™ program provides an in-depth review of topics covered in a June 2020 virtual symposium. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with in advanced renal cell carcinoma (RCC), putting recent clinical trial data into context. The program is designed both for those who did not attend the live meeting and to help reinforce learnings for those who did.
Acknowledgment of Commercial Support.This educational activity is supported by educational grants from Eisai, Inc; Exelixis, Inc; and Merck & Co, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists interested in the treatment of RCC. Urologists, nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with RCC will also be invited to participate.
Upon completion of this activity, participants will be able to:
- Review the pathobiology of RCC, and the therapeutic rationales for using targeted therapies and immunotherapies, both as single agents and in combination regimens
- Assess new and practice-changing data from clinical trials evaluating systemic agents such as targeted therapies and immunotherapies across multiple lines of therapy for advanced/metastatic RCC
- Outline strategies to monitor and mitigate adverse events associated with targeted agents and immunotherapies used in the treatment of advanced/metastatic RCC
- Consider the efficacy and safety of systemic therapies, as well as biomarkers, disease characteristics, comorbidities, and patient preferences, in order to individualize and optimize treatment for patients with advanced/metastatic RCC
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Director, Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Leader, Kidney Cancer Program
Dana-Farber/Harvard Cancer Center
Jerome and Nancy Kohlberg Chair and Professor of Medicine
Harvard Medical School
Disclosures: Grant Research Support: Analysis Group, AstraZeneca, Alexion, Bayer, Bristol Myers Squibb/ER Squibb and Sons LLC, Cerulean, Eisai, Inc, Foundation Medicine Inc, Exelixis, Inc, Ipsen, TRACON, Genentech, Roche, Roche Products Limited, F. Hoffmann-La Roche, GlaxoSmithKline, Lilly, Merck, Novartis, Peloton, Pfizer, Prometheus Labs, Corvus, Calithera, Sanofi- Aventis, Takeda; Consultant: Analysis Group, AstraZeneca, Alexion, Sanofi-Aventis, Bayer, Bristol Myers Squibb/ER Squibb and Sons, LLC, Cerulean, Eisai, Inc, Foundation Medicine Inc, Exelixis, Inc, Genentech, Heron Therapeutics, Inc, Lilly, Roche, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, EMD Serono, Prometheus Labs, Corvus, Ipsen, Up-to-Date, National Comprehensive Cancer Network
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Deputy Director, Cedars-Sinai Cancer
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosures: Grant Research Support: Exelixis, Inc, Calithera, Merck, Bristol Myers Squibb; Consultant: Merck, Arrowhead, Bristol Myers Squibb, Eisai, Inc, Apollomics, Inc
Chief, Medical Oncology, Beth Israel Deaconess Medical Center
Leader, Dana Farber/Harvard Cancer Center Kidney Cancer Program
Professor of Medicine, Harvard Medical School
Disclosures: Grant Research Support: BMS, Pfizer, Merck, Alkermes, Inc, Genentech, X4 Pharmaceuticals, Exelixis, Inc; Consultant: BMS, Pfizer, Merck, Alkermes, Inc, EMD Serono, Eli Lilly and Company, Iovance, Eisai, Inc
Department of Medical Oncology & Experimental Therapeutics
City of Hope Comprehensive Cancer Center
Chair, SWOG Renal Cancer Center Translational Medicine
Disclosures: Consultant: Astellas, Aveo, Bristol-Myers Squibb, Eisal, Exelixis, Genentech, Ipsen, Novartis, Pfizer, Roche
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.